Levosimendan Farmak

Levosimendan, the active ingredient in Levosimendan Farmak, is a calcium sensitizer presented as an injectable solution for intravenous use. It is employed to improve cardiac contractility in patients with acute decompensated heart failure or cardiogenic shock.

GNH USA supplies Levosimendan Farmak as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring quality and regulatory compliance across markets.

Levosimendan is used in the management of acute heart failure syndromes where enhanced cardiac output is required.

- Acute decompensated heart failure: improves ventricular contractility and reduces filling pressures. - Cardiogenic shock: supports hemodynamics while maintaining systemic vascular resistance. - Post‑cardiac surgery low‑output syndrome: facilitates weaning from mechanical support.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension - Headache - Nausea - Tachycardia - Dizziness - Flushing

Serious or Rare Side Effects: - Severe hypotension - Arrhythmias (including ventricular tachycardia) - Myocardial ischemia - Allergic reactions (anaphylaxis) - Pulmonary edema - Elevated liver enzymes

When using Levosimendan, clinicians should observe specific safety measures.

- Hemodynamic monitoring: continuously assess blood pressure and cardiac output during infusion. - Electrolyte balance: correct potassium and magnesium abnormalities before administration. - Renal function: adjust use in severe renal impairment due to reduced clearance. - Concomitant vasodilators: avoid excessive hypotension by titrating doses carefully. - Pregnancy and lactation: use only if potential benefits justify potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroprusside): may cause profound hypotension. - Strong CYP450 inhibitors: can increase levosimendan plasma concentrations. - Severe renal impairment: risk of drug accumulation and toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the desired inotropic effect. - Diuretics: may exacerbate electrolyte disturbances. - Nitrates: additive vasodilatory effect may require dose adjustment.